Browse the research platforms

Joint LYSA / LYSARC research platforms

The LYSA independent clinical research network and its operational structure LYSARC have implemented joint, very specialised research platforms that are essential to clinical and ancillary lymphoma studies

  • EARLY platform for early clinical phases: Conducting phase I/IIa clinical studies in the specific field of lymphoma research
  • LYSA-IM imaging platform: Network review of imaging examinations
  • LYSA-P pathology platform: Centralised review of tumour samples
  • LYSA-BIO biology platform: Pre-analytical management of biological samples

EARLY platform for early clinical phases

The EARLY platform enables phase I/IIa clinical studies in the specific field of lymphoma research. It is based on the LYSA expert centre network and the competences of the dedicated LYSARC operational team.

  • Structured and reactive management of early clinical trials , including the 1st tests on humans, 1st application to the lymphoma, 1st combined application
  • Extensive experience, with more than 40 phase I/IIa studies designed and successfully conducted
  • Extended access to patients through the LYSA expert sites network, labelled “early phase CLIP2 centres” by the French National Cancer Institute (13 phase I LYSA centres and 25 phase IIa LYSA centres)
  • ClinTrial Refer LYSA application to accelerate patient inclusion: informing doctors in real time about current clinical studies

Download the presentation leaflet for the Early platform (in English) (.pdf)

LYSA-IM imaging platform

The LYSA-IM platform is dedicated to the networked review of imaging examinations in clinical lymphoma research projects. It is based on nuclear medicine doctors, radiologist experts in lymphomas and a LYSARC specialised technical team.

  • Nearly 5,000 images reviewed/year: positron-emission tomography (PET), tomodensitometry (TDM), Magnetic Resonance Imaging (MRI)
  • More than 10,000 examinations in the proprietary database
  • Review in less than 48 hours of the examinations that are essential for protocol treatments (responses in the course of the treatment for example)
  • Capacity for autonomous research programs and ancillary studies (ex. measure of the metabolic tumour volume)
  • Independent review committee
  • International collaborations: Italy (FIL), USA (MSKCC), Denmark (Copenhagen), the Netherlands (VU University), UK (Saint Thomas Hospital), Australia (Concord Hospital)
  • Centralised, FDA-approved web exchange platform for imaging reviews: Imagys® software (collaboration with the French company Keosys)

Site: Henri Mondor teaching hospital at Créteil (France)

Download the presentation flyer of the imaging platform dedicated to lymphomas (.pdf)

LYSA-P digital pathology platform

The LYSA-P platform is dedicated to the centralised review of tissue samples taken from lymphoma patients. It is based on expert blood disease doctors of the international cooperating group LYSA and a specialised technical team of the operational structure LYSARC.

  • More than 20,000 cases reviewed so far 
  • A large collection of clinically annotated tumours: slides (classic, digitalised), paraffin blocks, frozen samples, TMA, DNA/RNA)
  • Automated high throughput analysis on large patient cohorts
  • Capacity for histopathology, digital pathology, morphometric research
  • State-of-the-art technological equipment, for digitalisation, analysis and sharing microscopic slides

Site: Henri Mondor teaching hospital at Créteil (France)

Download the presentation flyer of the digital pathology platform LYSA-P (.pdf)

LYSA-BIO biology platform

The LYSA-BIO biology platform is dedicated to the pre-analytical management of the biological samples in clinical lymphoma studies. It includes various experts and has the logistical and technical support of dedicated LYSARC staff.

  • Collection, marking, management of samples (plasma, DNA/RNA, fresh blood, fresh cells) in a controlled environment.
  • Personalised blood analyses
  • Specific genetic analyses
  • Capacity for studying residual disease, immunomonitoring

Sites: Lyon-Sud, Rennes and Créteil